Across TCGA pan-cancer cohorts, SP6 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SP6 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SP6 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SP6 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where SP6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.405	0.910	.001	22	view →
PDAC	DFS	Median	All	0.101	0.804	.010	17	view →
HNSC	DFS	Tertile	All	1.000	0.597	.043	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SP6 tumor-vs-normal RNA expression · all SP6 data types